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Background: Pancreatic cancer (PancCa) is recognized as a component of many well-described hereditary cancer
syndromes. Minimal research has focused on patient needs and experiences living with this risk.
Purpose: To understand the meaning and experience of living with familial PancCa risk and to explore experiences
related to screening and prevention of PancCa.
Methods: Participants underwent semi-structured, in-depth interviews. Adults without PancCa and who met familial
or hereditary risk criteria were eligible. Thematic analysis was completed on the transcripts in order to identify patterns,
consistencies, and differences. Narrative review of existing literature related to women living with hereditary breast and
ovarian cancer (HBOC) risk was completed to explore similarities and differences between published findings and
our current findings.
Results: Nineteen individuals (9 male, 10 female) participated. Major themes addressed participants’ family
experiences with PancCa and PancCa death and the associated grief from the experiences. Family experiences
impacted how participants interpreted and approached their own cancer risk and participated in the cancer
screening program. Participants wanted to control their cancer risk and sought information and resources to
prevent PancCa or PancCa related death. Distress related to risk was not described as constant but occurred
around salient time points.
Conclusion & future implications: Study results begin to describe the lived experience of individuals with
PancCa risk. Through this research we have uncovered important variables to further understand, measure, and
intervene upon in future research. Distress related to risk was not described as ongoing, but occurred around
specific and salient time points that brought risk to the forefront. Individuals with familial PancCa risk may have a
unique experience compared to other hereditary cancer syndromes due to the high mortality of the disease and
uncertainty related to prevention and early detection outcomes.
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In 2030 pancreatic cancer (PancCa) is expected to be the
second leading cause of cancer related death in the
United States [1]. Of the 46,420 estimated individuals in
the U.S. who were diagnosed with PancCa in 2014, 85 %
of those diagnosed will die from the disease [2]. If
PancCa is stage IA when diagnosed, an individual has a
5-year survival rate of 14 %, compared to 100 % [3] and
92 % [2] in stage I breast and colon cancer, respectively.
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unless otherwise stated.survival rate is only 1–3 % [2]. Because there are few
signs and symptoms of PancCa, most patients are diag-
nosed at a late, incurable stage. While overall rates of
cancer and cancer death have been declining, rates of
PancCa diagnosis have been increasing 1.5 % per year
since 2004 and death rates increased 0.4 % each year
from 2004–2008 [4].
Within the general population, an individual has ap-
proximately a 1.41 % lifetime risk for developing PancCa
[4]. However, PancCa is now considered both a familial
risk related cancer and a component of hereditary cancer
predisposition syndromes [5]. Based on consensus
agreement [6], individuals are considered at high riskal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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degree relatives or any three or more relatives, includ-
ing at least one first degree relative, have a diagnosis of
PancCa. Additionally, individuals with Peutz-Jeghers
Syndrome and those with p16, Hereditary Breast and
Ovarian Cancer Syndrome (HBOC) or BRCA1/2, ATM,
PALB2, or Lynch syndrome gene mutations and one or
more first degree relatives with PancCa are also considered
at risk [4–6] due to genetic factors. Individuals who meet
these criteria have higher risk burden ranging from a life-
time risk of 3.6 to 40 % [5, 6]. Consequently individuals
with elevated risk live with the awareness that if diagnosed
with PancCa most will die.
If a person is identified as being at risk for PancCa, a
healthy lifestyle, including tobacco cessation [6] or
weight loss [4], is recommended. Additionally, consensus
based guidelines from the International Cancer of the
Pancreas Screening Consortium (CAPS) [6] recommend
PancCa screening with endoscopic ultrasound (EUS) or
magnetic resonance imaging (MRI). If a lesion that is a
precursor to cancer is identified, individuals are recom-
mended to seek care at a specialty care center that has
experience with high risk PancCa [6].
With well-established and well-studied cancer syn-
dromes, such as HBOC and hereditary colon cancer
syndromes, there is evidence of psychosocial distress
associated with cancer risk [7]. Factors such as psycho-
social distress, perceptions of cancer risk and cancer
worry, and perceived ability to control cancer risk all
influence psychosocial outcomes in people with hereditary
breast or colon cancers [7–15]. Additionally, within these
cancer risk syndromes, risk perception is known to impact
both health behaviors and quality of life [16].
In contrast, there are limited data regarding patient re-
ported psychosocial outcomes in PancCa. Most studies
focus on measuring outcomes at set time points after
genetic counseling or surveillance [17–19]. These studies
have not documented clinically significant distress over
time in relation to genetic testing or surveillance. However,
those with high risk perception and baseline psychosocial
distress did experience distress post-testing and during
surveillance. Ethnographic work with 13 individuals
with a family history of PancCa or a BRCA2 mutation
demonstrated that limited knowledge about pancreatic
risk, insurance coverage, learning of a cancer diagnosis,
and the complexity of recommendations were all im-
portant components of how individuals approached
PancCa screening [18]. Screening is only one component
of living with PancCa risk. The magnitude of the po-
tential psychosocial impact on surviving family mem-
bers is vast and largely unexplored within this domain.
Clinicians will not have the tools to assess and then
subsequently intervene to improve psychosocial out-
comes for individuals and families living with PancCarisk until the context of this experience is described
and measured.
Therefore, the purpose of this study was to explore
how individuals with high risk for inherited or familial
PancCa experience live with this risk. Aims were to: (1)
understand what it means to live with the awareness of
high risk for inherited or familial PancCa and (2) explore
experiences as part of a comprehensive cancer prevention




The Dana-Farber Cancer Institute (DFCI) Institutional
Review Board reviewed and approved this study. Partici-
pants were recruited from the Gastrointestinal Cancer
Genetics and Prevention Program either in person at a
scheduled clinic visit or over the telephone by clinical
staff that were part of the research team. Eligible partici-
pants were over the age of 21 and did not have a PancCa
diagnosis. Participants all had personal, genetic, or familial
factors that implicated elevated PancCa risk, as verified by
medical record review. Specifically, all participants came
from a unique family in which two or more members had
a diagnosis of PancCa, and were first degree relatives of
one of the affected cases, or the participant had a known
hereditary cancer syndrome (based on germline genetic
testing demonstrating a pathogenic mutation) that is
associated with elevated pancreatic cancer risk plus any
family history of PancCa. Written informed consent
was completed prior to each interview.
Study design and process
This was a descriptive phenomenological study utilizing
qualitative interviews, which aimed for in-depth exploration
of an unexplored phenomenon [20]. Data were collected
through a single one-on-one, in-person interview. The first
author, trained in qualitative methods, completed all
interviews. The semi-structured interviews began by
asking participants to “Think back to when you first
learned that you were at increased risk for PancCa and
describe that experience.” The interviewer prompted
discussion of the following topics if the participant did
not discuss the topic independently: 1) What does
PancCa risk mean to you?; 2) What information is im-
portant for you to know about PancCa risk?; 3) How do
you feel about PancCa screening and what, if any,
screenings have you had?; and 4) What advice would you
give someone else living with PancCa risk? All participants
were asked to discuss any additional relevant information
not covered in the questions at the conclusion of the inter-
view. A brief demographic survey was reviewed with each
participant and family history data was extracted from the
medical record. All interviews were audio recorded and
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Analysis
Data analysis was completed in Nvivo 9. Thematic con-
tent analysis was used to identify key themes within the
interviews [21, 22]. The research team engaged in ana-
lysis led by the primary author (M.U.). First, a random
subset of the interviews was analyzed independently by
the research team and overall themes were identified to
develop a coding schema. Then, the primary author
reviewed all of the interviews to code for the identified
themes. Any additional themes or discrepancies identi-
fied were reviewed until consensus was reached and data
was re-analyzed. New participants were enrolled and
data collected until saturation of themes, or redundancy
in data, occurred [22]. After data were analyzed, results
were verified through comparison to existing literature
and by consensus of the research team which consisted
of clinicians and researchers. Measures of central ten-
dency were used to describe the demographic data.
Results
Description of sample
Forty eligible patients were approached to participate in
the study, sixteen were lost to follow-up, and five de-
clined. Nineteen participants (9 male and 10 female)
consented to the study and were interviewed, with inter-
views lasting 60 to 120 min. Table 1 describes the study
sample, including information pertaining to personal,
genetic, and family history. As indicated in the table,
most participants had familial PancCa risk. The sample
had a median of 3 (range 2–6) affected individuals
within the family. Cancers of the breast, ovaries, colon,
prostate, stomach, and melanoma also were mentioned
as occurring within the families; breast and ovarian were
most common.Table 1 Description of study sample
Median (range)




High school 2 (10.5)
College or some college 5 (26.3)
Graduate school 12 (63.2)




Prior medical history Breast cancer 2 (10.5)
Endometrial cancer 1 (5.3)
Chronic pancreatitis 1 (5.3)Overview
Three primary themes and nine subthemes were identified
in the analysis. Exemplar quotations for each theme are
listed in Table 2 and in the results below.
Theme 1: experiencing cancer risk in the family
Grieving The initial interview question asked participants
to describe the experience of learning about PancCa risk.
Most participants responded with a conversation about
family experience, while two individuals related a personal
cancer (non-PancCa) experience. Even for participants with
known genetic mutations predisposing them to cancer, it
was the family experience with cancer and death that was
paramount to how the participants discussed PancCa risk.
Participants were emotional when remembering the loss of
their loved ones. Specifically, participants who had close
relationships with loved ones that had died of PancCa were
grieving the loss. For example, one woman described how
when she learned of her own risk for PancCa, she re-
evaluated her happiness in her life, work, and living
situation. She stated:
[I am]…just kind of making plans for sort of easing
out of what’s a very stressful career and doing something
completely different, sort of what my heart wants to do
instead of what needs to be done to pay the mortgage. I
think some of that is driven by sort of…I could have
thirty years [or] I could have two days because I could
get hit by a car in the street. Pancreatic cancer though,
the possibility of that, I think made me stop and think
more carefully about it.
Of the 15 participants who described the time frame
in which they witnessed PancCa in the family, only two
had experiences within the past year. All others told de-
tailed stories of lost loved ones from years, even decades,
prior. The four individuals who did not describe a time-
frame for witnessing PancCa in the family shared stories
in the past tense, not the present.
Considering and planning for one’s own mortality
Witnessing multiple family members die of cancer raised
the participant’s awareness of the potential for developing
cancer or experiencing cancer related death. One partici-
pant referred to PancCa as a “death sentence,” which was a
common sentiment as no participants had witnessed a
loved one survive a PancCa diagnosis. During the inter-
views, those participants who experienced the death of a
loved one with PancCa in the past discussed end of life care
wishes and a desire to avoid a similar death experience.
One man, with a BRCA2 gene mutation and a father who
had died of PancCa, discussed in detail his end of life care
wishes and how they were impacted by the fear of dying
the way his father died.
Table 2 Themes and exemplar quotations




Grieving “I can never forget this–it’s blazed in my mind. My husband was
standing—I had come in the house, walked by him; we were
chatting, and he said, “I have something serious to tell you. Your
cousin passed away.” Right behind him was my son, who was
young. And I just lost it, started crying. I think knowing that it hit
our generation, the third generation, it’s very upsetting (crying).
…”




“…my brother and I kind of half-joke about this a lot, we’re not
going to see seventy-five, you know, so this sense of mortality is
very present lately. I’ve started to almost countdown back-
wards…I have thirty years, which is different than I’ve lived, so
now I’m going to die quicker than I’ve lived…over-the-hill has
passed already…”
40 year old male, BRCA2 gene mutation,
father passed away at age 70 from
pancreatic cancer
Experiencing fear “My male cousin, first cousin got pancreatic cancer and died
when he was fifty three and my aunt…also died at about 78…so
it’s just always in the back of my mind… You know, Are we
going to die from this? Is this our death sentence waiting for
us?—it’s made me very focused on being afraid of cancer in
general.”
64 year old female, familial pancreatic
cancer
“I don’t worry about hypertension. I don’t worry about car
crashes. I don’t worry about strokes. There’s a false positive that
gets created, which is, you know, by being twelve, or fourteen
percent likely to die of pancreatic cancer, you get it in your head
that you are going to die of pancreatic cancer, like when you’re
driving and you focus on a tree, you could go hit it. But the
inverse, of course, that there is an eight-six percent chance that
you are going to die from something else. And for some reason
that isn’t on my mind, and I don’t know why, other than it’s
unknown…”




Wanting to be taken
care of
“I’m not concerned because I have total faith in the doctors. If
the cancer shows up they’ll take care of me…”
66 year old female familial pancreatic
cancer
Approaching health “I try to live healthy, you know? I don’t drink. I don’t smoke.” 62 year old female, pancreatitis
“So you really do have to live for the day and enjoy it.” 62 year old female, BRCA2 gene
mutation, history of breast cancer
I started exercising—I’m up to once a week—I have lived a
sedentary lifestyle… I need to start exercising; I’ve cut back on
cigar smoking excessive alcohol. There is a consciousness that if I
am only going to make it into my seventies, I want to try to at
least be healthy…I don’t want to be decrepit in my sixties if I
have only so many years to go. I don’t ever think any of those
things are going to help me extend.
40 year old male, BRCA2 gene mutation,





“… it’s not like a heart attack. You don’t die overnight or you
don’t die kind of instantly… it’s a real rollercoaster. And you see
them slowly losing weight, and losing weight, and losing weight
and just sort of becoming you know so terribly frail and thin, you
know really to the point where you know they really are skin and
bones.
59 year old female, Lynch syndrome
…I don’t know if it’s somewhat subconscious or whatever that I
just seem to feel most comfortable at an overweight weight. I’m
trying to pack it on so that I have more to give up as opposed to
being the ideal weight, and then getting sick and then losing
precious body mass, or organ mass or whatever that at least if
I’ve got some extra fat on me then I can burn that off while
either I’m trying to get better, or they find a cure or whatever, ifs
I can come up with in my brain.”
58 year old male, BRCA2 gene mutation
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Table 2 Themes and exemplar quotations (Continued)
“A friend of mine asked me if you have pancreatic cancer what
will you do? And I was like right now I’d say that…I’d get a
house on the water, and I’ll read and I’ll just enjoy what I got left,
watch the sunsets and watch the sun rises. [the friend asked] You
wouldn’t do chemo? You won’t do radiation and all? The way I
feel right now, no, because I watched too many people go





try and catch cancer
early
“…if there was ever anything that it (pancreatic cancer screening)
would be able to—to be caught early. So that’s—that’s the
only—that’s the only hope, right, you can have.”
37 year old female, BRCA2 gene mutation
Uncertain benefit of
screening
“I’m comforted by the screening, but what’s the end result of the
screening? Am I going to lose my pancreas if something is
found? That’s the first thing I said to my brother, well, my
attitude was I’m not getting screened if they can’t cure it
because I don’t want to know that I have it or that I’m going to
have it in ten years or highly likely to if there’s no way to cure.”
54 year old male, familial pancreatic
cancer; undergoing screening
Anticipating results “So around the time of the procedure I start to get a little
anxious, like what are we going to learn this year, but once it’s
(screening) over …it’s over. “
58 year old female, familial pancreatic
cancer
Underhill et al. Hereditary Cancer in Clinical Practice  (2015) 13:13 Page 5 of 9Individuals expressed that it was difficult to discuss
mortality and dying of PancCa with their own family
and children. Participants had to “compartmentalize”
their risk or worry to protect family and planned to
avoid having their children experience cancer death as
they had in the past.
Pending mortality was discussed within the context of
age. Although participants were aware of risks related to
heart disease or other chronic illness, due to the significant
family experience related to PancCa, participants focused
on cancer alone as the cause of future death.
Experiencing fear Participants also discussed fear and
worry about developing PancCa. Furthermore, partici-
pants feared dying in pain or discomfort, as many had
watched loved ones die in that manner. Participants
feared placing a burden on loved ones to care for them
at the end of life.
This fear and worry was not reported as constant, but
experienced at specific and salient time points when the
participant was reminded of family experiences or personal
risks. These time points included screening or doctors’
visits, anniversaries of loved ones’ deaths, reaching the age
of a loved one who died of PancCa, and witnessing another
person with cancer, either a friend or a media figure.
Theme 2: seeking a way to control cancer risk
Wanting to be taken care of Participants felt “taken
care of” by PancCa expert clinicians and “grateful” for
the opportunity to be cared for in a way that deceased
family members had not experienced. Participants aimed
to avoid similar experiences of a PancCa related death,
and felt that access to specialists offered more “control”for both early detection and prevention. Participants dis-
cussed that having access to specialists was not a re-
source available to their family members in the past and
therefore they were grateful for the resources.
Receiving information for self-care was one aspect of
being cared for by clinical experts. Participants sought
recommendations related to lifestyle behaviors that were,
or were not, important to reduce PancCa risk, and these
helped guide self-care decision making. Most partici-
pants were also a part of a medical research study and
wanted research results shared with them. For some
participants finding helpful specific information was
challenging because PancCa was not considered a
“popular” disease and therefore not the focus of main-
stream media. As one participant stated, “…it’s [PancCa]
not breast cancer. It’s not…heart disease. It’s not sexy.”Approaching health Being aware of one’s own PancCa
risk led some individuals to live healthfully. Participants
discussed diet, exercise, reduced alcohol consumption,
and tobacco use as important factors to reduce cancer
risk. However, for some the experience of PancCa-
related death in the family led to a feeling that life
should be lived in the moment and to the fullest. One
participant described alcohol consumption as a potential
risk factor for PancCa, but reported enjoying alcohol
and stated “…it’s not as if I put down the wine.” Living
each day to the fullest was mentioned more frequently
by those who have had illness in the past, including an-
other cancer diagnosis. Those individuals who had not
had a personal diagnosis of cancer spoke more often
about modifying risk factors to avoid cancer.
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pants described a need to take action related to their
knowledge of PancCa risk, which is what led them to seek
care at the cancer center. The goal discussed by partici-
pants was to avoid a cancer death experience as seen
within the family. There were no stories of survivorship
within the participants’ families and all had witnessed one
or more loved ones die of the disease. PancCa had meant
pain and suffering.
One participant felt so strongly that seeking specialty
care was important, that despite a limited budget coming
to the cancer center was a priority. Taking part in research
was another strategy that participants described to avoid a
similar experience and helping other family members
avoid the same cancer death. As one woman described “…
this [research participation] isn’t really for me. It is for my
children and my grandchild.”Theme 3: undergoing PancCa screening
Doing something to try and catch cancer early Engaging
in PancCa screening was one way most participants
aimed to “do something”. For these participants, screen-
ing consisted of EUS and MRI. Participants spoke of
“not looking forward to” PancCa screening, but felt it to
be a necessary part of their health care. Engaging in
screening was a mechanism to be monitored closely and
frequently by a clinical expert. PancCa screening was
labeled as “prevention” and participants discussed that
they hoped to avoid what been their family member's
experience and to catch cancer when it was potentially
curable.Uncertain benefit of screening Participants discussed
concerns about the efficacy of screening, though most
still chose to undergo screening as a mechanism to “be
watched.” Only one male participant chose not to
undergo cancer screening, stating “… you guys don’t
have any real screening device for this yet…” The partici-
pant felt that undergoing screening created exposure to
risks associated with the procedures and tests and pro-
vided little benefit. In contrast, a female participant had
undergone a surgical procedure related to findings from
PancCa screening and felt that this was an important
strategy to reduce PancCa risk.
The outcome of screening over time was also a discus-
sion point within the interviews. One participant wanted
to undergo screening, but was not interested unless it led
to an ability to cure any identified cancer, and asked “what
is the end result?” While this participant chose to undergo
screening at the time of the interview, he questioned the
uncertainty of what would be done with the information
from the screening outcome.Anticipating results
Participants discussed experiencing worry or fear while
awaiting screening results that may have indicated an
abnormal finding. These concerns began in anticipation
of the screening appointment. One participant noted
irritability or anxiety the week before the screening
appointment, yet was unaware of these emotions until it
was acknowledged by a coworker. Another recognized
that entering the cancer center to complete the screening
caused “flashbacks” to familial experiences and fear of find-
ing cancer in themselves at this screening visit. Learning
the results of the procedure in a timely manner was helpful
to alleviate fear or worry after completing screening.
Discussion
This study was a descriptive phenomenological study
that aimed to begin to describe the meaning and lived
experience of living with PancCa risk (aim 1) in the con-
text of a high risk cancer center and screening program
(aim 2). Our findings indicate that family experience,
specifically an experience with cancer death, was an im-
portant component of how the participant approached
cancer risk. Participants sought a way to control cancer
risk and avoid an experience similar to that of family
members through healthy behavior and, for most,
screening, despite having fear of the results and being
uncertain about the efficacy of the procedure. There was
a sense of contradiction and uncertainty related to per-
ceptions of the efficacy of screening and a desire to avoid
death from PancCa. Access to specialists gave partici-
pants a mechanism to feel “taken care of” by experts was
a source of comfort. Participants felt it was challenging
to find and interpret information related to preventing
and detecting PancCa risk and wanted access to infor-
mation from health care experts.
Participants in this study felt that living with risk for
PancCa was at times an uncertain experience, specifically
related to knowing how to prevent or detect PancCa. The
familial experience was the most important component of
how these participants viewed their own PancCa risk. Stor-
ies of long-term survivorship in PancCa did not exist within
participants’ families because all of the family members
with PancCa died. This contributed to feelings of worry
and uncertainty related to PancCa risk, prevention, and
screening. In contrast, previous work completed with
women at high risk for HBOC and undergoing breast
cancer screening and prevention found that women
were confident in their ability to detect, treat, and cure
breast cancer if found [15]. Therefore, we see the import-
ance of strong clinical recommendations in impacting par-
ticipant confidence in their ability to live with risk.
Participants talked about not only avoiding cancer, but,
more specifically, avoiding a similar cancer experience to
that which they had witnessed in the family. Avoidance of
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reliving this experience, often involving more than one
family member, was emotional to discuss. Similarly,
Petrin et al. presented stories from participants who are
family caregivers of persons with pancreatic cancer and
described how these caregivers experienced worry and
fear about their own future cancer risk and wanted to
avoid the same cancer related death experience. Partici-
pants also discussed a long term psychological impact
from caring for a loved one with PancCa [23], which is
similar to that described by our participants. Our study
provides further evidence that when caring for those
with hereditary or familial cancer risk, care needs to
extend beyond just identifying and managing risk, but
to acknowledgement of the grief associated with losing
loved ones to cancer.
Within this sample, participants described a psycho-
social response to living with familial pancreatic cancer
risk, such as worry and fear, which has been reported in
previous literature [24]. These psychological responses
were not constant, occurred over the course of the indi-
vidual’s life, and were present during times that caused
the person to remember familial experiences with
PancCa. This brings to light the need for psychosocial
support for persons living with this risk, not only for
managing their own risk, but in coming to terms with a
significant familial cancer experience. A similar need has
been reported previously and, in a study of 248 Dutch
participants with HBOC or HBOC risk, it was reported
that individuals may need psychological support regard-
less of having a “diagnosed” psychological disorder [25].
Only one third of individuals in the Dutch study who re-
quested psychosocial support received support, which
provides further evidence of a potential gap in care for
those with hereditary cancer risk that, as we have identified,
includes those with familial pancreatic cancer risk.
Previous literature supports that at risk individuals are
willing to take part in pancreatic cancer risk reduction
and screening interventions [24, 26]. Our findings
present background as to why participants may be re-
ceptive to these interventions and demonstrate the sali-
ence of family experience on influencing health choices.
Participants sought ways to control cancer risk and
sought care and support from clinical experts. For this
study, care was sought from the comprehensive cancer
prevention program. Participants described feeling grate-
ful for having access to this resource and also reported
that they felt that they had fewer resources compared to
people with other cancer risk. The screening and pre-
vention mechanisms, and what to do with the resultant
information, for PancCa are evolving, and participants
shared uncertainty related to outcomes associated with
both lifestyle choices and screening EUS or MRI. In light
of the lack of evidence which fully supports screening,participants relied on clinical experts to guide them in
making health choices. It is important that clinical re-
search continues to test these mechanisms for screening
so that clinicians can have the tools to help fully inform
their patients.
Implications
In this study we began to understand the lived experience
of persons with high risk for PancCa. From this initial
study, we now understand important factors that will be
necessary components of future practice and research
endeavors. Practice related implications include a need to
provide information to and support access for individuals
living with high risk for PancCa. This includes not only
genetic risk related information, but also information
about self-care benefits, screening, and available psycho-
social support services to deal with grief associated with
familial loss.
Due to our findings that participants in this study had
cancer related fear and worry that were intermittent and
would flare up at certain times, individuals with high
PancCa risk may benefit from supportive psychosocial
intervention targeted to specific times, such as the weeks
prior to a screening appointment. Additionally, this fear
and worry often stemmed from witnessing family mem-
bers die of pancreatic cancer. Therefore, assessing if an
individual had a family death experience related to
PancCa could help identify psychosocial needs and will
be an important variable to measure in future research.
Implications also include ensuring psychosocial needs are
being adequately measured in future research and that in-
vestigators work to identify patient-centered time-points to
capture this information. The ultimate goal of this work
would be to develop a supportive care intervention tailored
to the needs of the participants. A crucial component of tai-
loring would be to confirm that the intervention is being
administered at a time that is impactful to the participant.
These individuals living with familial PanCa risk were
highly engaged in the health care system, and actively
seeking self-care information. Lawson & Flocke describe
this as a “teachable moment” where individuals experi-
ence a significant life event, such as witnessing a family
member die of cancer or learning of one’s own risk for
cancer, and are more likely to make a personal change
[27]. Breitkopf and colleagues further validate this model
in a sample of family members of persons with colo-rectal
cancer and find that participants who are family members
of individuals who have or had a diagnosis of colorectal
cancer are more willing to take part in a cancer prevention
intervention [28]. Therefore, future research interventions
targeting the population of caregivers of individuals with
PancCa could have the potential to positively impact both
medical and psychosocial outcomes. Future research should
also aim to include those who do not choose screening to
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and do not choose screening and also those from a more
diverse background.
Limitations
Our data are limited to stories from individuals who
agreed to participate and therefore might be different
from others who did not volunteer. Additionally, all of
the participants were receiving care at an academic cancer
center while findings may be different at other sites. We ac-
knowledge that the experiences of individuals taking part in
a high risk cancer prevention program may be different
from experiences in other clinical settings. Most work with
this population is currently being done in academic medical
centers and therefore this study is just a first step in de-
scribing the needs of this population. Future work will need
to expand recruitment to outside of the academic setting.
Finally, the participants in this study were well educated
with limited cultural or racial variability and therefore find-
ings may not reflect the reports of a more diverse sample.
Conclusion
Study results begin to describe the lived experience of
individuals with PancCa risk. Through this research we
have uncovered important variables to further understand,
measure, and intervene upon in future research, such as
fear, worry, and family experience. Distress related to risk
was not described as ongoing, but occurred around specific
and salient time points that brought risk to the forefront.
Individuals with familial PancCa risk may have a unique ex-
perience compared to other hereditary cancer syndromes
due to the high mortality of the disease and uncertainty
related to prevention and early detection outcomes.
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